A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B
Article first published online: 13 DEC 2005
Alimentary Pharmacology & Therapeutics
Volume 23, Issue 1, pages 99–106, January 2006
How to Cite
MANESIS, E. K., PAPATHEODORIDIS, G. V. and HADZIYANNIS, S. J. (2006), A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B. Alimentary Pharmacology & Therapeutics, 23: 99–106. doi: 10.1111/j.1365-2036.2006.02731.x
- Issue published online: 13 DEC 2005
- Article first published online: 13 DEC 2005
- Publication data Submitted 7 August 2005 First decision 31 August 2005 Resubmitted 21 September 2005 Resubmitted 11 October 2005 Accepted 14 October 2005
Treatment of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHBe-) with interferon or lamivudine alone is inefficient and reports of combination treatment with both drugs, equivocal so far.
To investigate the efficacy of a lamivudine–interferon combination therapy in 36 patients HBeAg-negative CHBe−.
Lamivudine was administered from 1 to 12 months and interferon-α2b from 7 to 18 months. A historical control group of 36 CHBe− patients, matched for age and sex and treated with the same dosage of interferon-α2b was used. All patients were followed up for ≥12-month post-treatment.
The biochemical response rate at the end of treatment was 78% in lamivudine–interferon and 52.8% in interferon–control group (P = 0.026) and at 12-month post-treatment 38.9% and 22.2%, respectively (P = 0.125). Alanine aminotransferase normalization and serum HBV-DNA levels ≤30 000 cp/mL were observed in 50.0% of lamivudine–interferon-treated and 30.6% of interferon-treated patients at the end of treatment (P =0.093) and in 22.2% and 13.9% of patients, respectively, at 12-month post-treatment (P = 0.358). Moreover, alanine aminotransferase normalization and undetectable serum HBV-DNA (<400 cp/mL) was observed in 30.6% of lamivudine–interferon-treated and 8.3% of interferon-treated patients at the end of treatment (P = 0.017) and in 8.3% and 0% of patients, respectively, at 12-month post-treatment (P = 0.076).
In CHBe−, 12 months after ending a lamivudine–interferon partially overlapping 18-month combination course, 22% of patients still maintain normal alanine aminotransferase and HBV-DNA levels ≤30 000 cp/mL. However, a 12-month interferon monotherapy course may achieve similar responses.